Guggenheim Starts Rapport Therapeutics (RAPP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts RAPP Hot Sheet
Price: $25.64 -1.12%
Rating Summary:
15 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
15 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ: RAPP) with a Buy rating and a price target of $65.00.
For an analyst ratings summary and ratings history on Rapport Therapeutics click here. For more ratings news on Rapport Therapeutics click here.
Shares of Rapport Therapeutics closed at $32.17 yesterday.
You May Also Be Interested In
- Rapport Therapeutics (RAPP) PT Lowered to $64 at UBS
- Citi Assumes Genting Malaysia Bhd (GENM:MK) (GMALF) at Buy
- Citi initiates ATI Inc. coverage with Buy rating, $229 target
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
